Dr. Paul Helbling, did his Master’s degree in Biology at the University of Zurich, and obtained his PhD in Developmental Biology at the Swiss Federal Institute of Technology (ETH) in Zurich. After his PhD he worked at the Foundation for Cardiovascular Research and organized clinical studies according to GCP. He moved on to MDS Pharma Services where he held various positions in the GLP compliant facilities, finally responsible for the ligand binding group that specialized in the analysis of biologics and anti-drug antibodies. His next position was in business development at the GMP compliant facilities of Solvias AG, responsible for southern Europe and Germany and opening new market territories in Turkey. He then became Head of Business Development at IBR Inc. a GLP-compliant service provider specialising in cell-based assays. Finally, he joined the team at Dualsystems as CEO that is focusing on identifying targets and off-targets on the living cells using LC-MS/MS.
Paul Helbling is fully responsible for the daily management of Dualsystems, reporting to the Board of Directors.